當(dāng)前位置：首頁(yè) JCRQ1 期刊介紹(非官網(wǎng))

Infectious Diseases And TherapySCIE

國(guó)際簡(jiǎn)稱：INFECT DIS THER 參考譯名：傳染病與治療

中科院分區(qū)
3區(qū)
CiteScore分區(qū)
Q1
JCR分區(qū)
Q1

基本信息：: ISSN：2193-8229; E-ISSN：2193-6382; 是否OA：開(kāi)放; 是否預(yù)警：否; TOP期刊：否

出版信息：: 出版地區(qū)：ENGLAND; 出版商：Springer Healthcare; 出版語(yǔ)言：English; 出版周期：6 issues per year; 出版年份：2012; 研究方向：Medicine-Microbiology (medical)

評(píng)價(jià)信息：: 影響因子：4.7; CiteScore指數(shù)：8.6; SJR指數(shù)：1.351; SNIP指數(shù)：1.311

發(fā)文數(shù)據(jù)：: Gold OA文章占比：98.50%; 研究類文章占比：77.78%; 年發(fā)文量：144; 自引率：0.0185...; 開(kāi)源占比：0.9927; 出版撤稿占比：0; 出版國(guó)人文章占比：0.04; OA被引用占比：1

投稿咨詢加急見(jiàn)刊

英文簡(jiǎn)介期刊介紹 CiteScore數(shù)據(jù) 中科院SCI分區(qū) JCR分區(qū) 發(fā)文數(shù)據(jù) 常見(jiàn)問(wèn)題

英文簡(jiǎn)介Infectious Diseases And Therapy期刊介紹

Infectious Diseases and Therapy is an international, open access, peer-reviewed, rapid publication journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of infectious disease therapies and interventions, including vaccines and devices. Studies relating to diagnostic products and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged.

Areas of focus include, but are not limited to, bacterial and fungal infections, viral infections (including HIV/AIDS and hepatitis), parasitological diseases, tuberculosis and other mycobacterial diseases, vaccinations and other interventions, and drug-resistance, chronic infections, epidemiology and tropical, emergent, pediatric, dermal and sexually-transmitted diseases.

期刊簡(jiǎn)介Infectious Diseases And Therapy期刊介紹

《Infectious Diseases And Therapy》自2012出版以來(lái)，是一本醫(yī)學(xué)優(yōu)秀雜志。致力于發(fā)表原創(chuàng)科學(xué)研究結(jié)果，并為醫(yī)學(xué)各個(gè)領(lǐng)域的原創(chuàng)研究提供一個(gè)展示平臺(tái)，以促進(jìn)醫(yī)學(xué)領(lǐng)域的的進(jìn)步。該刊鼓勵(lì)先進(jìn)的、清晰的闡述，從廣泛的視角提供當(dāng)前感興趣的研究主題的新見(jiàn)解，或?qū)彶槎嗄陙?lái)某個(gè)重要領(lǐng)域的所有重要發(fā)展。該期刊特色在于及時(shí)報(bào)道醫(yī)學(xué)領(lǐng)域的最新進(jìn)展和新發(fā)現(xiàn)新突破等。該刊近一年未被列入預(yù)警期刊名單，目前已被權(quán)威數(shù)據(jù)庫(kù)SCIE收錄，得到了廣泛的認(rèn)可。

該期刊投稿重要關(guān)注點(diǎn)：

預(yù)計(jì)審稿時(shí)間： 6 Weeks
醫(yī)學(xué)
INFECTIOUS DISEASES
SCIE
中科院3區(qū)
非預(yù)警

Cite Score數(shù)據(jù)（2024年最新版）Infectious Diseases And Therapy Cite Score數(shù)據(jù)

CiteScore：8.6
SJR：1.351
SNIP：1.311

學(xué)科類別	分區(qū)	排名	百分位
大類：Medicine 小類：Infectious Diseases	Q1	61 / 344	82%
大類：Medicine 小類：Microbiology (medical)	Q1	31 / 140	78%

CiteScore 是由Elsevier(愛(ài)思唯爾)推出的另一種評(píng)價(jià)期刊影響力的文獻(xiàn)計(jì)量指標(biāo)。反映出一家期刊近期發(fā)表論文的年篇均引用次數(shù)。CiteScore以Scopus數(shù)據(jù)庫(kù)中收集的引文為基礎(chǔ)，針對(duì)的是前四年發(fā)表的論文的引文。CiteScore的意義在于，它可以為學(xué)術(shù)界提供一種新的、更全面、更客觀地評(píng)價(jià)期刊影響力的方法，而不僅僅是通過(guò)影響因子(IF)這一單一指標(biāo)來(lái)評(píng)價(jià)。

歷年Cite Score趨勢(shì)圖

中科院SCI分區(qū)Infectious Diseases And Therapy 中科院分區(qū)

中科院 2023年12月升級(jí)版 綜述期刊：否 Top期刊：否

大類學(xué)科	分區(qū)	小類學(xué)科	分區(qū)
醫(yī)學(xué)	3區(qū)	INFECTIOUS DISEASES 傳染病學(xué)	3區(qū)

中科院分區(qū)表 是以客觀數(shù)據(jù)為基礎(chǔ)，運(yùn)用科學(xué)計(jì)量學(xué)方法對(duì)國(guó)際、國(guó)內(nèi)學(xué)術(shù)期刊依據(jù)影響力進(jìn)行等級(jí)劃分的期刊評(píng)價(jià)標(biāo)準(zhǔn)。它為我國(guó)科研、教育機(jī)構(gòu)的管理人員、科研工作者提供了一份評(píng)價(jià)國(guó)際學(xué)術(shù)期刊影響力的參考數(shù)據(jù)，得到了全國(guó)各地高校、科研機(jī)構(gòu)的廣泛認(rèn)可。

中科院分區(qū)表 將所有期刊按照一定指標(biāo)劃分為1區(qū)、2區(qū)、3區(qū)、4區(qū)四個(gè)層次，類似于“優(yōu)、良、及格”等。最開(kāi)始，這個(gè)分區(qū)只是為了方便圖書管理及圖書情報(bào)領(lǐng)域的研究和期刊評(píng)估。之后中科院分區(qū)逐步發(fā)展成為了一種評(píng)價(jià)學(xué)術(shù)期刊質(zhì)量的重要工具。

歷年中科院分區(qū)趨勢(shì)圖

JCR分區(qū)Infectious Diseases And Therapy JCR分區(qū)

2023-2024 年最新版

按JIF指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：INFECTIOUS DISEASES	SCIE	Q1	20 / 132	85.2%

按JCI指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：INFECTIOUS DISEASES	SCIE	Q1	32 / 132	76.14%

JCR分區(qū)的優(yōu)勢(shì)在于它可以幫助讀者對(duì)學(xué)術(shù)文獻(xiàn)質(zhì)量進(jìn)行評(píng)估。不同學(xué)科的文章引用量可能存在較大的差異，此時(shí)單獨(dú)依靠影響因子(IF)評(píng)價(jià)期刊的質(zhì)量可能是存在一定問(wèn)題的。因此，JCR將期刊按照學(xué)科門類和影響因子分為不同的分區(qū)，這樣讀者可以根據(jù)自己的研究領(lǐng)域和需求選擇合適的期刊。

歷年影響因子趨勢(shì)圖

發(fā)文數(shù)據(jù)

2023-2024 年國(guó)家/地區(qū)發(fā)文量統(tǒng)計(jì)

國(guó)家/地區(qū)數(shù)量
USA96
England21
Italy21
GERMANY (FED REP GER)16
Belgium14
Canada14
CHINA MAINLAND13
France13
Spain13
Netherlands11

本刊中國(guó)學(xué)者近年發(fā)表論文

1、Non-invasive Assessment of Liver Fibrosis Regression in Patients with Chronic Hepatitis B: A Retrospective Cohort Study
Author: Xu, Wei; Hu, Qiankun; Chen, Chong; Li, Weixia; Li, Qiang; Chen, Liang

Journal: INFECTIOUS DISEASES AND THERAPY. 2023; Vol. 12, Issue 2, pp. 487-498. DOI: 10.1007/s40121-022-00738-1
2、Retrospective Analysis of Epidemiology, Risk Factors, and Outcomes of Health Care-Acquired Carbapenem-Resistant Klebsiella pneumoniae Bacteremia in a Chinese Tertiary Hospital, 2010-2019
Author: Li, Meng; Yang, Shanshan; Yao, Hongwu; Liu, Yunxi; Du, Mingmei

Journal: INFECTIOUS DISEASES AND THERAPY. 2023; Vol. 12, Issue 2, pp. 473-485. DOI: 10.1007/s40121-022-00732-7
3、Association Between Lactate and 28-Day Mortality in Elderly Patients with Sepsis: Results from MIMIC-IV Database
Author: He, Liudang; Yang, Donghua; Ding, Qiong; Su, Yingjie; Ding, Ning

Journal: INFECTIOUS DISEASES AND THERAPY. 2023; Vol. 12, Issue 2, pp. 459-472. DOI: 10.1007/s40121-022-00736-3
4、Comparison of the Distribution and Changes in the Antibiotic Resistance of Clinical Bacterial Isolates from the Lower Respiratory Tract of Children in Shenzhen Before the Epidemic, During the Epidemic, and During the Period of Normalized Prevention and Control of COVID-19
Author: Meng, Qing; Li, Wujiao; Jiang, Hanfang; Yan, Huimin; Wang, Heping; Ye, Binjun; Zhou, Lintao; Chen, Yunsheng

Journal: INFECTIOUS DISEASES AND THERAPY. 2023; Vol. 12, Issue 2, pp. 563-575. DOI: 10.1007/s40121-022-00751-4
5、The Association Between Alveolar-Arterial Oxygen Tension Difference and the Severity of COVID-19 in Patients
Author: Xie, Canbin; Deng, Jiayi; Li, Fanglin; Wu, Chenfang; Xu, Min; Yu, Bo; Wu, Guobao; Zhong, Yanjun; Tang, Da; Li, Jinxiu

Journal: INFECTIOUS DISEASES AND THERAPY. 2023; Vol. 12, Issue 2, pp. 577-587. DOI: 10.1007/s40121-022-00752-3
6、Safety and Efficacy of Paxlovid Against Omicron Variants of Coronavirus Disease 2019 in Elderly Patients
Author: Weng, Chengzhao; Xie, Rongcheng; Han, Guanjie; Yuan, Ya; Li, Shiqin; Wang, Chao; Wang, Xiaofeng; Jiang, Wei; Jiang, Libo

Journal: INFECTIOUS DISEASES AND THERAPY. 2023; Vol. 12, Issue 2, pp. 649-662. DOI: 10.1007/s40121-023-00760-x
7、Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Anti-C5a Antibody BDB-001 for Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Trial in Healthy Chinese Adults
Author: Chen, Guiling; Li, Nan; Dai, Xiahong; Tu, Shiyan; Shen, Zhenwei; Wu, Kaiqi; Jin, Tinghan; Wu, Jiajun; Peng, Conggao; Sheng, Guoping; Zhu, Mengfei; Tang, Lingling; Li, Lanjuan

Journal: INFECTIOUS DISEASES AND THERAPY. 2023; Vol. 12, Issue 2, pp. 663-675. DOI: 10.1007/s40121-023-00759-4
8、Effect of Anti-HBs on Mortality Among Resolved HBV Infection: a Population-Based Prospective Cohort Study
Author: Huang, Shuai-Wen; Li, Xi-Tang; Chen, Chen; Ning, Qin; Huang, Jia-Quan

Journal: INFECTIOUS DISEASES AND THERAPY. 2023; Vol. 12, Issue 3, pp. 871-890. DOI: 10.1007/s40121-023-00766-5